



## Monroe Livingston Region Program Agency

---


*Division of Prehospital Medicine, University of Rochester*

Mailing Address: 601 Elmwood Avenue, Box 655, Rochester, NY 14642

Physical Address: 120 Corporate Woods, Suite 100, Rochester, NY 14623

Phone: (585) 463-2900 Fax: (585) 473-3516 E-Mail: [mlrems@mlrems.org](mailto:mlrems@mlrems.org)

To: All ALS Providers and Agencies

From: Jeremy T. Cushman, MD, MS, EMT-P   
Regional Medical Director

Date: December 19, 2013

Re: Advisory 13-14: Intranasal Naloxone for BLS Providers

---

In the summer of 2012 the Rochester Fire Department began participating in a statewide pilot project to determine the safety and appropriateness of adding intranasal naloxone to the BLS scope of practice. This project has been tremendously successful, and the NYS DOH Bureau of EMS recently added the intranasal administration of naloxone to the BLS scope of practice. Their policy statement and statewide BLS protocol is attached. MLREMS Protocol 2.25 Poisoning/Overdose has been updated to reflect the addition of naloxone to the BLS scope of practice and is also attached. This protocol is effective immediately.

Agencies wishing to add naloxone to their scope of practice are expected to do the following:

1. Perform a use analysis to determine the likelihood and therefore value of adding a BLS naloxone program.
2. Meet with the agency medical director, review the use analysis, and when appropriate, obtain agency medical director authorization.
3. Create and submit the following policies and procedures to the REMAC for review:
  - a. EMS training, credentialing and continuing education as it relates to intranasal naloxone
  - b. Process for documentation of credentialed users
  - c. Naloxone medication policies to include
    - i. Inventory
    - ii. Storage, including environmental considerations
    - iii. Security
    - iv. Disposal of medication and administration devices
4. Outline a defined quality assurance program, including appropriateness review by the agency medical director.
5. Obtain naloxone and mucosal atomizers as described and maintain the program and administer according to regional protocol and the NYS DOH BEMS policy statement.
6. Provide the Program Agency with evidence of the above and the REMAC will be notified of the intent to provide BLS naloxone.
7. Submit all uses of BLS naloxone to the Program Agency for regional quality assurance purposes.

With any questions, please do not hesitate to contact our office.